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Summary
Background Evidence for the effectiveness of treatments in early-onset psychosis is sparse. Current guidance for the 
treatment of early-onset psychosis is mostly extrapolated from trials in adult populations. The UK National Institute 
for Health and Care Excellence has recommended evaluation of the clinical effectiveness and cost-effectiveness of 
antipsychotic drugs versus psychological intervention (cognitive behavioural therapy [CBT] and family intervention) 
versus the combination of these treatments for early-onset psychosis. The aim of this study was to establish the 
feasibility of a randomised controlled trial of antipsychotic monotherapy, psychological intervention monotherapy, 
and antipsychotics plus psychological intervention in adolescents with first-episode psychosis.
Methods We did a multicentre pilot and feasibility trial according to a randomised, single-blind, three-arm, controlled 
design. We recruited participants from seven UK National Health Service Trust sites. Participants were aged 
14–18 years; help-seeking; had presented with first-episode psychosis in the past year; were under the care of a 
psychiatrist; were showing current psychotic symptoms; and met ICD-10 criteria for schizophrenia, schizoaffective 
disorder, or delusional disorder, or met the entry criteria for an early intervention for psychosis service. Participants 
were assigned (1:1:1) to antipsychotics, psychological intervention (CBT with optional family intervention), or 
antipsychotics plus psychological intervention. Randomisation was via a web-based randomisation system, with 
permuted blocks of random size, stratified by centre and family contact. CBT incorporated up to 26 sessions over 
6 months plus up to four booster sessions, and family intervention incorporated up to six sessions over 6 months. 
Choice and dose of antipsychotic were at the discretion of the treating consultant psychiatrist. Participants were 
followed up for a maximum of 12 months. The primary outcome was feasibility (ie, data on trial referral and 
recruitment, session attendance or medication adherence, retention, and treatment acceptability) and the proposed 
primary efficacy outcome was total score on the Positive and Negative Syndrome Scale (PANSS) at 6 months. Primary 
outcomes were analysed by intention to treat. Safety outcomes were reported according to as-treated status, for all 
patients who had received at least one session of CBT or family intervention, or at least one dose of antipsychotics. 
The study was prospectively registered with ISRCTN, ISRCTN80567433.
Findings Of 101 patients referred to the study, 61 patients (mean age 16·3 years [SD 1·3]) were recruited from 
April 10, 2017, to Oct 31, 2018, 18 of whom were randomly assigned to psychological intervention, 22 to antipsychotics, 
and 21 to antipsychotics plus psychological intervention. The trial recruitment rate was 68% of our target sample size 
of 90 participants. The study had a low referral to recruitment ratio (around 2:1), a high rate of retention (51 [84%] 
participants retained at the 6-month primary endpoint), a high rate of adherence to psychological intervention 
(defined as six or more sessions of CBT; in 32 [82%] of 39 participants in the monotherapy and combined groups), 
and a moderate rate of adherence to antipsychotic medication (defined as at least 6 consecutive weeks of exposure to 
antipsychotics; in 28 [65%] of 43 participants in the monotherapy and combined groups). Mean scores for PANSS 
total at the 6-month primary endpoint were 68·6 (SD 17·3) for antipsychotic monotherapy (6·2 points lower than at 
randomisation), 59·8 (13·7) for psychological intervention (13·1 points lower than at randomisation), and 62·0 (15·9) 
for antipsychotics plus psychological intervention (13·9 points lower than at randomisation). A good clinical response 
at 6 months (defined as ≥50% improvement in PANSS total score) was achieved in four (22%) of 18 patients receiving 
antipsychotic monotherapy, five (31%) of 16 receiving psychological intervention, and five (29%) of 17 receiving 
antipsychotics plus psychological intervention. In as-treated groups, serious adverse events occurred in eight [35%] of 
23 patients in the combined group, two [13%] of 15 in the antipsychotics group, four [24%] of 17 in the psychological 
intervention group, and four [80%] of five who did not receive any treatment. No serious adverse events were 
considered to be related to participation in the trial.
Interpretation This trial is the first to show that a head-to-head clinical trial comparing psychological intervention, 
antipsychotics, and their combination is safe in young people with first-episode psychosis. However, the feasibility of 
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Introduction
Early-onset psychosis refers to the development of a first 
episode of psychosis before the age of 18 years, with 
estimates in the UK suggesting an incidence rate of 
5·9 per 100 000 people.1 Adolescence is a period of 
substantial change in bio logical, social, and psychological 
development, and those with early-onset psychosis face 
additional challenges. Compared with psychosis in 
adults, the long-term prog nosis of early-onset psychosis 
can be poor, particularly in relation to functional 
outcomes, worse overall outcomes, and greater numbers 
of hospitali sations and relapses.2 The risk of poor long-
term outcomes appears to be increased by premorbid 
difficulties, a long duration of untreated psychosis, and 
severe symptoms at baseline assessment.3 The risk of 
suicidal behaviour has been shown to be greater in young 
people with psychosis than in those with other mental 
health problems.4 In addition to personal costs, early-
onset psychosis also accounts for a considerable pro-
portion of inpatient admissions and economic costs.5
In 2015, a systematic literature review indicated that 
for young people with psychosis the mainstay of 
treatment is antipsychotic drugs.6 However, the evidence 
base for the effectiveness of antipsychotics in early-
onset psychosis is sparse compared with in adult 
psychosis. Although a previous meta-analysis indicated 
that anti psychotics have a small but significant benefit 
over placebo treatment on total, positive, and negative 
symptoms (Positive and Negative Syndrome Scale 
[PANSS]), social functioning, and a significant effect on 
improvement in global state (Clinical Global Impression 
Scale), this evidence comes from a small number of 
a larger trial is unclear because of site-specific recruitment challenges, and amendments to trial design would be 
needed for an adequately powered clinical and cost-effectiveness trial that provides robust evidence.
Funding National Institute for Health Research.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Research in context
Evidence before this study
We searched PubMed for articles published from database 
inception up to Dec 10, 2019, with the terms “schizophrenia”, 
“psychosis”, “psychological therapy”, “psychosocial 
intervention”, “CBT”, “family intervention”, “antipsychotic”, 
“neuroleptic”, “child*”, “adolescent”, “young person”, and “first 
episode psychosis”, without language restrictions. One 
systematic review identified seven placebo-controlled trials of 
antipsychotic medication for young people with psychosis 
(aged <18 years), and the subsequent meta-analysis indicated 
small but significant effects of antipsychotics on psychotic 
symptoms and a moderate and significant adverse effect on 
weight gain. We identified no trials of psychological 
intervention in a population strictly younger than 18 years. A 
systematic review and network meta-analysis of antipsychotics 
identified 28 randomised controlled trials (RCTs) of 
antipsychotics for children or adolescents (aged 7–18 years) 
with psychosis. Results of the pairwise meta-analyses indicated 
a benefit of a number of antipsychotics over placebo treatment 
for overall psychotic symptoms, and the network meta-analysis 
indicated that clozapine was superior to all other antipsychotics 
for total, positive, and negative symptoms. However, network 
meta-analysis relies on the use of indirect as well as direct 
evidence, and, with regard to clozapine, only two studies were 
available that directly compared clozapine to another 
antipsychotic. Since publication of these systematic reviews, 
two further trials of antipsychotics and one feasibility RCT of 
psychological intervention in young populations (<18 years) 
have been published. No head-to-head trials have compared 
the clinical or cost-effectiveness of pharmacological, 
psychological, and combined pharmacological and 
psychological treatment in adolescents with psychosis.
Added value of this study
The present trial showed that a methodologically rigorous 
clinical trial that randomly assigns young people with psychosis 
to psychological treatment, pharmacological treatment, or their 
combination, is possible. Our study suggests that antipsychotic 
medication, psychological intervention (cognitive behavioural 
therapy plus family intervention), and a combination of the 
two are acceptable, safe, and helpful treatments for young 
people with first-episode psychosis, with all three treatments 
seeming to provide benefit in terms of symptoms (Positive and 
Negative Syndrome Scale total score) and recovery 
(Questionnaire about the Process of Recovery total). 
No findings suggested that psychological interventions in the 
absence of antipsychotic medication were detrimental.
Implications of all the available evidence
An adequately powered efficacy and effectiveness trial is now 
required. Such a trial could test hypotheses regarding 
superiority (eg, combined treatment being superior to 
monotherapies for effectiveness) and non-inferiority 
(eg, between monotherapies). Our preliminary findings appear 
consistent with current UK National Institute for Health and 
Care Excellence guidelines (CG155) that recommend informed 
choices and shared decision making regarding treatment 
options for early-onset psychosis on the basis of cost-benefit 
profiles.
Articles
790 www.thelancet.com/psychiatry   Vol 7   September 2020
low-quality studies and the placebo groups also showed 
improvement, on average, to a clinically significant 
extent in psychiatric symptoms.6 Additionally, concern 
has been expressed over the increased risk of adverse 
metabolic side-effects of antipsychotics in young people, 
with weight gain being particularly problematic.7,8
With regard to psychological interventions for psychosis, 
a systematic review of the literature found no studies of 
either cognitive behavioural therapy (CBT) or family 
intervention in people younger than 18 years.6 Eight low-
quality studies of CBT and family intervention in people 
younger than 25 years showed a small but significant 
effect of combination therapy with CBT and family inter-
vention on the number of days to relapse.6 Since 2015, 
when Stafford and colleagues6 did their systematic review 
search, one small (n=30), non-randomised feasi bility 
study of CBT versus family intervention versus treatment 
as usual has been done in a psychosis population younger 
than 18 years, which showed the feasibility of recruiting 
people with early-onset psychosis to a trial comparing 
psychological interventions.9
At present, the evidence for the effectiveness of treat-
ments for early-onset psychosis is scarce and treatment 
recommendations of the UK National Institute for Health 
and Care Excellence (NICE) for psychological interventions 
(clinical guideline CG155)10 are extrapolated from the 
larger adult psychosis evidence base, which was considered 
sufficiently strong to make the current recommendations 
of antipsychotics, CBT, and family intervention. The 
paucity of evidence specific to young people is recognised 
in the NICE clinical guideline CG155, on psychosis and 
schizophrenia management in children and young people, 
and led to a research recommendation for an evaluation 
of the clinical effectiveness and cost-effectiveness of 
antipsychotics versus psychological inter vention versus a 
combination of both in adolescents with early-onset 
psychosis.10 To inform a definitive trial, in the present study 
we investigated the feasibility of a randomised controlled 
trial of antipsychotic mono therapy, psychological inter-
vention monotherapy, and anti psychotics plus psycho-
logical intervention in adolescents with first-episode 
psychosis.
Methods
Study design
We did a multicentre pilot and feasibility trial according 
to a randomised, single-blind, three-arm, controlled 
design, recruiting individuals at UK National Health 
Service (NHS) Trusts located at seven sites (Birmingham, 
Greater Manchester, Lancashire, Oxfordshire and 
Buckinghamshire, Northumberland Tyne and Wear, 
Norfolk and Suffolk, and Sussex). This trial, named 
the Managing Adolescent first episode Psychosis: a feasi-
bility Study (MAPS), was approved by the North West–
Greater Manchester East Research Ethics Committee on 
Feb 6, 2017 (reference 16/NW/0893). The protocol, 
approved by an independent data monitoring committee 
and indepen dent trial steering committee, is available 
online and provided in the appendix (p 29). Six substantial 
protocol amend ments were submitted to and approved 
by the research ethics committee, which are described in 
full in the appendix (pp 5–7).
Participants
Eligible participants were aged 14–18 years; help-seeking; 
presented with first-episode psychosis (defined as being 
within 1 year of presentation to mental health services with 
psychosis symptoms); under the care of a psychiatrist 
within an Early Intervention in Psychosis (EIP) service or 
Child and Adolescent Mental Health Service (CAMHS); 
symptomatic at the time of random isation (baseline), 
defined by a score of 4 or higher on the PANSS delusions 
or hallucinations subscales for at least 7 consecutive days; 
and met either the ICD-10 criteria for schizophrenia, 
schizoaffective disorder, or delusional disorder, or the 
entry criteria for an EIP service for first-episode psychosis 
at baseline. All participants had to have the capacity to 
provide informed, written consent to enter the trial. 
Participants aged 14–15 years also needed to have a parent 
or guardian willing to provide initial written consent for 
the research team to contact their child.
Individuals who met any of the following criteria were 
excluded: receipt of antipsychotics or structured psycho-
logical intervention within the past 3 months; non-
English speaking; scored 5 or higher on the PANSS 
conceptual disorganisation item (to maximise the 
likelihood that those allocated to talking therapies would 
be able to engage in conversation with the therapist); 
were deemed an immediate risk to themselves or others 
by their psychiatrist or care coordinator; diagnoses of 
moderate-to-severe learning disabilities, ICD-10 organic 
psychosis, or primary alcohol or substance dependence.
Participants were referred to the study by mental health 
staff (primarily psychiatrists and care coordinators) within 
EIP or CAMHS teams across the seven sites. Research 
assistants completed baseline assess ments including the 
PANSS to determine eligi bility. Assessments generally 
took place within partici pants’ homes, schools or colleges, 
or within clinical services. All baseline PANSS assessments 
were reviewed by a qualified clinician working on the trial 
to confirm eligibility before randomisation.
All participants provided written informed consent 
before their participation in the trial.
Randomisation and masking
Participants were randomly allocated in a 1:1:1 ratio to 
receive either antipsychotic medication, psychological 
intervention, which comprised CBT plus optional 
family intervention at the participant’s discretion, or a 
combi nation of both antipsychotics and psychological 
inter vention. Research assistants randomly assigned 
partici pants using a secure web-based random isation 
system developed by the University of Aberdeen Centre 
for Healthcare Randomised Trials (CHaRT; Aberdeen, 
For the trial protocol see https://
www.journalslibrary.nihr.ac.uk/
programmes/hta/153104/#/
See Online for appendix
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UK), a UK Clinical Research Collaboration clinical 
trials unit. Randomisation was done in permuted 
blocks of random size, stratified by centre and family 
contact (to account for participants allocated to receive 
psychological inter vention who did not have regular 
family contact). Randomisation was independent and 
concealed at the individual level, with outcome 
assessors masked to treatment. The trial manager 
(MP), chief investigator (APM), therapists, and admin-
istrator were informed of participants’ allocations by 
email. Participants and their care teams received their 
allocation details via letter, and participants and 
psychiatrists were offered telephone calls to provide 
further details. A standard operating procedure for 
allocation concealment, reviewed and approved by the 
data monitoring and trial steering committees, was 
provided to all research staff, which highlighted the 
importance of allocation concealment and outlined 
potential sources of non-adherence to masking, and 
methods to maintain masking, including arrangements 
for separate offices and telephone num bers for research 
assistants and therapists and verbal reminders to 
participants, family members, and care team clinicians 
about the importance of masking. All research staff 
were required to sign a declaration to confirm that they 
would abide by the standard operating procedure while 
working on the trial. Breaks in allocation concealment 
were reported to the trial manager and chief investigator, 
with learning points disseminated to the study team, 
and to the independent data monitoring and indepen-
dent trial steering committees for monitoring.
Procedures
Participants allocated to receive psychological inter vention 
were offered up to 26 h of individual CBT and up to six 
optional sessions of family intervention (plus regular 
communication with family members following CBT 
sessions for individuals who consented to the sharing of 
information) by appropriately trained therapists over a 
6-month treatment period, and up to 4 booster sessions of 
CBT following the treatment period. CBT sessions were 
typically once a week and family intervention once a 
month, and were generally delivered by the same therapist. 
Both interventions were informed by an integrative 
cognitive model.11 In the initial phase of CBT, patients and 
therapists collaboratively identified problems and agreed 
on goals to work on in CBT and an individualised main-
tenance formulation was developed. Subsequent phases 
focused on change strategies with interventions described 
in a published manual,12 historical formulations (ie, factors 
leading to the development of first-episode psychosis), and 
a final consolidation phase focusing on relapse prevention. 
Family intervention was based on the behavioural family 
therapy approach.13 After an initial session involving 
assessment, formulation sharing, and agreeing goals and 
problems to be worked on, family intervention involved 
aspects such as psycho educational work, provision of 
normalising information and recovery-oriented infor-
mation, problem solving, and relapse prevention planning. 
Therapy session records were completed by therapists 
throughout the delivery of psychological interventions, 
and therapists received supervision once a week from two 
MAPS group members (APM and SB). Audio-recorded 
CBT sessions, taped with the patient’s consent, were rated 
regularly via rotational sampling of tapes with the 
Cognitive Therapy Scale–Revised (by APM and SB) to 
ensure fidelity to the protocol.
For participants allocated to receive drug intervention, 
antipsychotics were prescribed by the treating psychiatrist 
in their care team. Psychiatrists were asked to prescribe 
in line with NICE guideline CG155. They were 
encouraged to commence treatment as soon as possible 
following randomisation and to maintain treatment for 
at least 3 months, but preferably for 6 months or longer. 
Psychiatrists made decisions about the type and dose of 
antipsychotic consistent with their usual practice, and 
could change antipsychotic and dose as clinically 
required in response to monitoring of efficacy and 
adverse effects. The psychiatrists within the MAPS team 
(DM, MRB, NH, AJ, PMH, RW, RU, and FP) were 
available by phone or email to discuss antipsychotic 
prescribing with the participant’s psychiatrist.
Participants allocated to receive antipsychotics plus 
psychological intervention were offered all treatments as 
described for the monotherapy groups. All participants 
in the trial were able to receive any other concomitant 
therapies throughout the trial including mental health 
medications (this could include antipsychotics in the 
psychological intervention group), and psychological 
therapies (this could include CBT or family intervention 
in the antipsychotics group). We collected data on 
concomitant therapies via self-report and medical record 
screening at follow-up visits at 3 months, 6 months, and 
12 months.
To address concerns about the safety of withholding 
antipsychotic medication to participants in the psycho-
logical intervention monotherapy arm, at 3 months after 
the start of intervention we assessed for any deterioration 
in rescaled PANSS total scores from the baseline 
assessment at randomisation. Any participant allocated to 
receive monotherapy (ie, anti psychotics only or psycho-
logical intervention only) with an increase of more than 
12·5% in PANSS, selected as a conservative thres hold to 
prioritise safety, was offered the combination therapy, as 
were any with a compulsory hospital admis sion and those 
deemed to be an immediate suicide risk. Such patients 
remained as participants in the trial and took part in 
follow-up assessments.
Outcomes
As MAPS is a feasibility study, our primary outcomes 
were trial referral and recruitment rates, participant 
attendance at CBT sessions, medication adherence, 
acceptability of treatments (determined by assessing 
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discontinuation rates, and by a nested qualitative study of 
participants being published in parallel14) and completion 
of follow-up appoint ments including PANSS interviews. 
To determine the feasibility of progression to a definitive 
trial, we applied a three-stage progression criteria relating 
to recruitment, retention to follow-up at the primary 
endpoint (6 months), and adherence to psychological 
intervention and to antipsychotics. The progression 
criteria were agreed with our independent trial steering 
committee, independent data monitoring committee, and 
funder. The specific progression criteria for each outcome 
were: recruitment of at least 80% of the planned 
population (green zone for progression), recruitment 
within 60–79% of the planned population (amber), or 
recruitment less than 60% of the planned population 
(red); retention of participants within the study with 
baseline and outcome assessments at the primary 
endpoint (6 months, end of treatment) with at least 80% 
having completed a PANSS interview (green), 60–79% 
having completed a PANSS interview (amber), or less 
than 60% having completed a PANSS interview (red); 
satisfactory delivery of adherent therapy to at least 80% of 
groups receiving psychological intervention (green), 
60–79% of groups receiving psychological intervention 
(amber), or less than 60% of groups receiving psycho-
logical intervention (red); and satisfactory delivery of anti-
psychotic medication to at least 80% of groups receiving 
antipsychotics (green), 60–79% of groups receiving anti-
psychotics (amber), or less than 60% of groups receiving 
antipsychotics (red). Satisfactory delivery of adherent 
psychological therapy was operation alised as attending 
six or more sessions of CBT. Satisfactory delivery of 
adherent antipsychotic medication was operationalised as 
any exposure to antipsychotics for at least 6 consecutive 
weeks (this could include a dose lower than the British 
National Formulary lower limits given this is a frequent 
clinical practice for people of this age, and the drugs are 
licensed for adults). As a further feasibility assessment, we 
intended to assess the pro portion of eligible people whom 
clinicians were willing to refer, but we were unable to 
capture these data syste matically.
We collected data on a number of secondary outcomes to 
assess their acceptability and usefulness for inclusion in a 
definitive trial. Secondary outcome measures were 
collected at baseline and at the follow-up visits at 3 months, 
6 months, and 12 months. We designed a variable length 
follow-up. Participants recruited in the first 16 months 
were followed-up for the full 12 months, and those 
recruited thereafter were offered assessments up to the 
end of treatment (6 months). Our prespecified proposed 
primary outcome measure for a definitive trial was total 
score on PANSS—a 30-item rating scale designed to assess 
psychopathology in people with a diagnosis of schizo-
phrenia15—with an endpoint of 6 months. We assessed 
difference in PANSS from baseline, and categorised 
improvement according to 25% (minimal improvement), 
50% (good clinical response), and 75% thresholds at each 
follow-up visit. Thresholds were selected and defined for 
the purposes of our study on the basis of previous 
recommendations regarding reporting of PANSS assess-
ments.16 We also assessed social and educational or 
occupational functioning (First Episode Social Functioning 
Scale), subjective recovery (Questionnaire about the 
Process of Recovery [QPR]), dimensions of paranoia, 
hallucinations, cognitive disorganisation, grandiosity, and 
anhedonia (Specific Psychotic Experiences Questionnaire), 
anxiety and depression (Hospital Anxiety and Depression 
Scale), and alcohol and drug use (Alcohol Use Disorder 
Identification Test and Drug Abuse Screening Test). At 
baseline, we measured diagnostic symptoms for autism 
spectrum conditions using the NICE-recommended 
10-item version of the Autism Spectrum Quotient. Health 
economics data were measured with an economic patient 
questionnaire adapted from our previous study,17 to assess 
NHS resource use, and the EuroQol five-dimension, 
five-level scale health status questionnaire. Further details 
regarding secondary outcomes are provided in the 
appendix (pp 2–3, 42–44).
At each follow-up visit, we also measured non-
neurological adverse effects with the Antipsychotic Non-
neurological Side-Effects Rating Scale18 and completed a 
cardiovascular screening comprising height, weight, 
blood pressure, waist circumference, and blood tests 
(total cholesterol, low-density lipoproteins, high-density 
lipoproteins, triglycerides, prolactin concen trations, 
glycated haemoglobin concentrations, and fasting 
plasma glucose). We recorded all serious adverse events 
and adverse events, including potential adverse effects of 
trial participation and deteriorations in PANSS score 
according to 12·5%, 25%, and 50% thresholds. Medical 
records were screened for details of adverse events at 
follow-up by a member of the research team who was not 
masked to allocation at each site, and self-reported 
adverse events were noted at follow-up or by therapists to 
the chief investigator and trial manager. Potential adverse 
effects associated with psychological intervention were 
monitored via a self-report measure developed in our 
previous trial (appendix pp 23–24).17 Full definitions of 
adverse events are provided in the appendix (p 2).
Diagnosis and antipsychotic prescribing were recorded 
via review of medical record case notes. The type, dose, 
and duration of each antipsychotic prescribed were 
recorded for each participant for the full 12-month trial 
period (or for 6 months for those recruited during the 
second stage of the variable follow-up).
Statistical analysis
A proposed sample size of 90 participants (30 per 
treatment arm) was considered sufficient to gain 
reliable information to inform sample size estimates 
for a larger trial19 and feasibility information about trial 
procedures. We did not do a formal power calculation 
to detect treatment differences, given that the focus of 
analysis was not hypothesis testing. The analysis 
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followed a prespecified statistical analysis plan agreed 
by the chief investigator and the data monitoring 
committee. All main analyses were according to the 
intention-to-treat principle and done at the participant 
level. Safety and unwanted effects were analysed on the 
basis of treatment received (as-treated) rather than as-
randomised, with psycho logical inter vention defined as 
any session of CBT or family inter vention from the trial 
therapist and antipsychotic treatment defined as 
any dose of an antipsychotic prescribed by the partici-
pant’s psychiatrist. We sum marised progression criteria 
using descriptive statistics, regarding the number of 
participants referred, the number of eligible referrals 
the number of consenting individuals and recruited 
individuals to each group, drop-out from the allocated 
intervention; withdrawal of consent, and absence of 
follow-up outcome data. We also report descriptive 
statistics for the components of psychological inter-
vention received, including number of sessions and 
milestones achieved, and completion of between-
session tasks. Additionally, we calculated the proportion 
of participants who received the allocated intervention 
versus the proportion that did not, and the proportion 
who moved to the combined arm due to deterioration. 
A repeated-measures analysis was done of the proposed 
primary outcome (total PANSS score) and the secondary 
outcome of subjective recovery (QPR; prioritised to 
assess recovery defined by service users), with a mixed-
effects model to account for the discrete timing of the 
follow-up assess ments and adjust for site and baseline 
score. We used all available data from each timepoint, 
and treatment effects were estimated at each timepoint 
with a treatment-by-time interaction. Missing baseline 
data was imputed with a centre-specific mean. Due to 
low response rates or low number of events, analyses 
for other variables were descriptive, but outcomes are 
reported in full. All analyses were done in Stata 
(version 15)20 at CHaRT. The focus of the analysis was 
on point estimates and associated 95% CIs rather than 
statistical significance (p values); however, we have 
reported p values for completeness in the appendix 
(p 10), but all analyses were underpowered and not 
based on a power calculation. The percentage change in 
total PANSS score was calculated with adjusted PANSS 
methodology.21 Descriptive data from baseline and 
follow-up visits were summarised as the mean (SD) or 
medians (IQR) for continuous data and frequencies 
and percentages for categorical variables. Full details of 
our statistical analyses are provided in the appendix (p 4). 
The study was prospectively registered on Feb 27, 2017, 
on the ISRCTN registry, ISRCTN80567433.
Role of the funding source
MAPS was funded by the UK National Institute for 
Health Research under its Health Technology Assessment 
Programme following a commissioned call (project 
number 15/31/04). The call specified the interventions, 
population, setting, study design, and main outcomes. 
The funder of the study had no role in data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data in 
the study and had final responsibility for the decision to 
submit for publication.
101 patients referred
29 excluded at referral
 5 declined participation*
  8 disengaged with research or clinical team
  3 deemed unsuitable for antipsychotics by
treating psychiatrist
  2 parents refused consent
  1 with a preference against antipsychotics
  1 with a preference against psychological
intervention
  6 did not meet inclusion criteria
  3 with other reasons†
72 screened
11 excluded at screening
9 scored <4 on PANSS P1 and P3
1 considered immediate risk to self or others
1 disengaged from service
61 randomly assigned
18 allocated to psychological
intervention
21 allocated to antipsychotics
plus psychological
intervention
22 allocated to antipsychotics
10 received allocated
intervention
8 did not receive allocated
intervention
11 received allocated
intervention
10 did not receive allocated
intervention
14 received allocated
intervention
8 did not receive allocated
intervention
17 completed 3-month 
assessment
1 withdrew
17 completed 3-month 
assessment
1 withdrew
3 lost to follow-up
19 completed 3-month
assessment
3 lost to follow-up
16 completed 6-month
assessment
1 withdrew
1 lost to follow-up
17 completed 6-month
assessment
1 withdrew
3 lost to follow-up
18 completed 6-month
assessment
4 lost to follow-up
11 completed 12-month
assessment
3 followed up for <12 months
1 withdrew
3 lost to follow-up
11 completed 12-month
assessment
4 followed up for <12 months
1 withdrew
5 lost to follow-up
9 completed 12-month
assessment
5 followed up for <12 months
 8 lost to follow-up
Figure: Trial profile
PANSS=Positive and Negative Syndrome Scale. P1=delusions. P3=Hallucinatory behaviour. *Reasons unknown. 
†Reasons are unknown; randomisation closed; and moved out of area.
For the statistical analysis plan 
see https://www.abdn.ac.uk/
hsru/what-we-do/trials-unit/
statistical-analysis-plans-611.php
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Results
Between April 1, 2017, and Oct 31, 2018, 101 patients were 
referred to the study. The first patient was recruited on 
April 10, 2017 and the last on Oct 31, 2018. We recruited 
61 participants (mean age 16·3 years [SD 1·3]): 18 to 
psychological intervention, 22 to antipsychotics, and 
21 to antipsychotics plus psychological intervention 
(figure). Baseline characteristics are summarised in 
table 1 and the appendix (p 8). Follow-up assessments 
were done between July 1, 2017 and April 30, 2019.
Regarding our feasibility criteria, our recruitment rate 
was 68% of the target sample size of 90 participants 
(amber progression zone); 51 (84%) participants were 
retained at the 6-month primary end point (green); and, as 
measures of satisfactory treatment delivery, 32 (82%) of 
39 assigned to psycho logical intervention (as monotherapy 
or in combination with antipsychotics) received six or 
more sessions of CBT (green), and 28 (65%) of 43 assigned 
to antipsychotics (as monotherapy or in combination with 
psychological intervention) were exposed to antipsychotics 
for 6 or more consecutive weeks (amber).
The referral to recruitment rate was about 2:1, with 
five (5%) of 101 referred patients declining to take part 
and only two (2%) parents declining consent to contact 
their child. The most common referring service type was 
the EIP, which referred 83 (82%) patients. Of the 
61 participants randomly assigned across UK NHS 
Trusts, most randomisations were done at the Oxford 
(25 [41%]) and Manchester (21 [34%]) sites. The number 
of participants with an ICD-10 diagnosis of a psychotic 
disorder in their medical records at baseline was 41 (67%), 
among whom the most commonly recorded diagnosis 
was unspecified non-organic psychosis (ICD-10 code 
F29; 40 [98%] partici pants). At the primary endpoint 
assessment at 6 months, only two patients had been 
withdrawn from the primary analyses (retained in 
assessments of safety) and attrition was low (figure). 
51 (84%) participants had been retained in the trial at the 
primary endpoint and had completed the PANSS total 
assessment (green progression zone). Retention at the 
12-month follow-up was lower: of 49 participants who 
were eligible for a 12-month assessment, 31 (63%) 
completed the follow-up (figure). The number of full 
blind breaks (ie, randomly assigned group revealed) was 
three, with two in the psychological intervention group 
and one in the antipsychotics group, all of which occurred 
before the 3-month follow-up visit. Seven partial blind 
breaks (ie, one treatment revealed to assessor) occurred 
at 3 months, seven at 6 months, and four at 12 months 
(four in the antipsychotics group, two in the psychological 
intervention group, and one in the combined group). Of 
the 135 follow-up assessments, seven (5%) were 
completed by an assessor with whom a full blind break 
had occurred and 12 (9%) were completed by an assessor 
with whom a partial blind break had occurred. The 
remaining breaks (full and partial) were transferred to a 
new and independent assessor.
32 participants in the psychological intervention groups 
(monotherapy or combined group) received six or more 
sessions of CBT, as our predefined feasibility criteria for 
adherent delivery. Of the seven participants assigned to 
psychological intervention who did not receive six sessions, 
Antipsychotics 
(n=22)
Psychological 
intervention 
(n=18)
Antipsychotics plus 
psychological 
intervention (n=21)
Age, years 16·4 (1·3) 16·3 (1·4) 16·2 (1·3)
Gender
Male 12 (55%) 8 (44%) 10 (48%)
Female 9 (41%) 10 (56%) 10 (48%)
Non-binary 1 (5%) 0 1 (5%)
Duration of untreated psychosis, months 15; 9 (3–14) 13; 12 (7–18) 16; 8 (2–18)
Highest level of education
Secondary 11 (50%) 9 (50%) 11 (52%)
Tertiary 11 (50%) 9 (50%) 10 (48%)
Employment status
College student 9 (41%) 7 (39%) 8 (38%)
Secondary school student 7 (32%) 5 (28%) 8 (38%)
Unemployed 2 (9%) 4 (22%) 2 (10%)
Full-time 3 (14%) 1 (6%) 1 (5%)
Part-time 1 (5%) 1 (6%) 1 (5%)
Voluntary 0 0 1 (5%)
Marital status, single 22 (100%) 18 (100%) 21 (100%)
Living arrangements
Parents and siblings 20 (91%) 15 (83%) 18 (86%)
Supported accommodation 1 (5%) 2 (11%) 1 (5%)
Other family members 0 1 (6%) 2 (10%)
Alone 1 (5%) 0 0
Ethnicity
White British 17 (77%) 14 (78%) 18 (86%)
Indian 0 1 (6%) 0
Pakistani 2 (9%) 0 1 (5%)
White Asian 0 0 1 (5%)
 Black African 1 (5%) 1 (6%) 0
 Black Caribbean 1 (5%) 0 1 (5%)
White Irish 1 (5%) 0 0
Other 0 2 (11%) 0
Religion
Atheism 12 (55%) 7 (39%) 10 (48%)
Christianity 4 (18%) 4 (22%) 4 (19%)
None 2 (9%) 6 (33%) 3 (14%)
Islam 2 (9%) 0 1 (5%)
Buddhism 0 0 1 (5%)
Other 2 (9%) 1 (6%) 2 (10%)
PANSS score
Total 74·8 (12·2) 72·9 (9·7) 75·9 (14·8)
Positive 22·9 (6·0) 21·2 (3·8) 21·2 (5·8)
Negative 17·9 (5·6) 15·8 (3·3) 18·5 (6·6)
Disorganised 19·9 (4·6) 20·1 (4·5) 21·0 (5·4)
Excitement 19·3 (4·1) 17·1 (3·7) 17·9 (4·9)
Emotional distress 24·7 (6·7) 25·2 (4·5) 24·8 (5·8)
(Table 1 continues on page)
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the reasons were participant disengagement after 
commencing CBT (four), participants declining therapy 
before commencing CBT (two), and participant withdrawal 
before six sessions (one). Three patients switched to 
antipsychotic monotherapy (two from the psychological 
intervention group and one from the combined group). 
The 18 participants assigned to psychological intervention 
monotherapy received a median of 14 sessions (IQR 9–23) 
of CBT and a median of three sessions (2–5) of family 
intervention, with nine participants receiving at least one 
session of family intervention. Only one participant 
received no sessions of CBT or family intervention. The 
21 participants assigned to combined treatment received a 
median of 15 sessions (IQR 9–17) of CBT and a median of 
four sessions (2–5) of family intervention, with 12 partici-
pants receiving at least one session of family intervention. 
Only one participant received no sessions. For all patients 
allocated to receive psychological intervention (mono-
therapy and combined groups), the median time to the 
first recorded CBT session was 15 days (IQR 6–44).
28 participants in the antipsychotic groups (mono-
therapy or combined group) were exposed to anti-
psychotics for 6 consecutive weeks, as our predefined 
feasibility criteria for satisfactory exposure. Of the 
15 participants assigned to antipsychotics who did not 
reach 6 weeks of exposure, the reasons were participants 
declining antipsychotics before prescription (three), 
clinicians not prescribing antipsychotics (three), both 
participant and family declining medication before 
prescription (one), and data that were unable to be 
extrapolated from medical records (eight). Seven patients 
switched to psychological intervention monotherapy 
from the combined group. Of those with adequate 
exposure to antipsychotics, the median duration of treat-
ment was 23 weeks (IQR 13–36) in the monotherapy 
group and 43 weeks (32–51) in the combined group 
(overall median 32 weeks [20–44]). For all patients 
allocated to receive antipsychotics (monotherapy and 
combined groups), the median time to prescription was 
18 days (IQR 10–42). 14 (33%) of the 43 participants 
assigned to antipsychotics switched from one anti-
psychotic drug to another during their involve ment in 
the study. Of the 43 prescriptions made, the most 
commonly prescribed was aripiprazole (21 prescriptions), 
risperidone (ten), and quetiapine (nine). Full details 
regarding the drugs prescribed, durations, and doses are 
given in the appendix (p 9).
Overall, the proportion of participants who received 
their allocated intervention was similar across groups, 
with a slightly higher proportion observed in the anti-
psychotics monotherapy group (table 2), and the 
majority of participants received treatment as allocated. 
Ten (56%) of 18 participants in the psychological 
intervention group, 14 (64%) of 22 in the antipsychotics 
group, and 11 (52%) of 21 in the combined group 
received an adherent dose of their allocated treatment 
(at least six sessions of CBT or 6 consecutive weeks of 
antipsychotics) as randomly assigned. As indicated in 
table 2, some participants received no treatment due to 
non-engagement with treat ment or non-adherence 
(10 [16%] of 61), and a minority received an unassigned 
treatment (eight [13%]).
In our intention-to-treat analysis of efficacy, we 
assessed adjusted PANSS total scores at 6 months, 
Antipsychotics 
(n=22)
Psychological 
intervention 
(n=18)
Antipsychotics plus 
psychological 
intervention (n=21)
(Continued from previous page)
PANSS symptom profiles
At least moderate hallucinations 
(PANSS P3 score ≥4)
21 15 18
At least moderate delusions (PANSS P1 
score ≥4, PANSS P6 score ≥5 and 
PANSS P5 score ≥5
14 13 14
At least moderate for both 13 10 11
Questionnaire about Process of Recovery 15; 42·1 (10·0) 12; 46·1 (9·3) 18; 42·6 (10·1)
AQ-10 11; 5·2 (1·8) 8; 4·8 (2·1) 10; 5·4 (2·1)
Participants with AQ-10 score greater 
than the clinical threshold (≥6)
6 (55%) 2 (25%) 4 (40%)
Hospital Anxiety and Depression Scale
Anxiety 15; 12·7 (4·0) 10; 11·2 (2·6) 13; 14·2 (2·5)
Score greater than the case threshold 
(≥11)
9 (60%) 5 (50%) 12 (92%)
Depression 15; 9·7 (5·1) 10; 9·2 (3·8) 13; 10·2 (4·4)
Score greater than the case threshold 
(≥11)
5 (33%) 3 (30%) 6 (46%)
Antipsychotic Non-neurological Side Effects Rating Scale
Total score 12; 15·9 (6·4) 8; 17·5 (10·4) 11; 17·2 (7·1)
Number of side effects 12; 11·2 (5·2) 8; 10·6 (4·8) 11; 11·5 (3·8)
Data are n, n (%), mean (SD), n; mean (SD), or n; median (IQR). Percentages do not always add up to 100% due to 
rounding. PANSS=Positive and Negative Syndrome Scale. P1=delusions. P3=hallucinatory behaviour. P5=grandiosity. 
P6=suspiciousness or persecution. AQ-10=10-item Autism Spectrum Quotient.
Table 1: Baseline characteristics
Antipsychotics 
(n=22)
Psychological 
intervention 
(n=18)
Antipsychotics plus 
psychological 
intervention (n=21)
Treatment received*
Psychological 
intervention
0 10 (56%) 7 (33%)
Antipsychotics 14 (64%) 2 (11%) 1 (5%)
Antipsychotics 
plus 
psychological 
intervention
2 (9%) 4 (22%) 11 (52%)
None† 6 (27%) 2 (11%) 2 (10%)
Adherence*
Overall 16 (73%)‡ 14 (78%)‡ 11 (52%)
*Six or more cognitive behavioural therapy sessions or 6 weeks of antipsychotic 
exposure. †Including the two participants who withdrew from the trial. ‡Including 
participants who received their assigned treatment in addition to an unassigned 
treatment.
Table 2: Randomly assigned treatment vs treatment received
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among those participants retained for this primary 
endpoint. Mean scores for PANSS total at the 6-month 
primary endpoint were 68·6 (SD 17·3) for antipsychotic 
monotherapy (6·2 points lower than at baseline), 59·8 
(13·7) for psycho logical intervention (13·1 points lower 
than at baseline), and 62·0 (15·9) for antipsychotics plus 
psycho logical intervention (13·9 points lower than at 
baseline) (table 3). PANSS score was improved by at least 
25% (minimal clinical improvement) in ten (63%) of 
16 partici pants in the psychological intervention group, 
five (28%) of 18 in the antipsychotics group, and 11 (65%) 
of 17 in the combined group (table 4) A good clinical 
response at 6 months (≥50% improvement in PANSS 
total score) was achieved in four (22%) of 18 patients 
receiving antipsychotic monotherapy, five (31%) of 
16 receiving psychological intervention, and five (29%) of 
17 receiving antipsychotics plus psychological inter ven-
tion. Mean QPR scores at 3–12 months are summarised 
in table 5. Compared with baseline, mean QPR score 
at the 6-month primary endpoint was increased by 
7·8 points in the antipsychotics group, 3·3 points in the 
psychological intervention group, and 8·7 points in the 
combined group. All other secondary outcomes and 
results of statistical tests of PANSS and QPR scores are 
reported in the appendix (pp 9–20).
In our as-treated assessment of safety in participants 
who received at least one dose or session, more patients 
experienced serious adverse events in the combined 
group (eight [35%] of 23 participants) than in the 
antipsychotics group (two [13%] of 15) and psychological 
intervention group (four [24%] of 17). The greatest 
proportion of patients with serious adverse events was in 
the no-treatment group (four [80%] of five). Table 6 
summarises adverse events and deteriorations in PANSS. 
No serious adverse events were deemed to be related to 
the trial regimens. Other adverse events were experienced 
in greater proportions in the antipsychotics group 
(13 [87%] patients) and combined group (16 [70%]) than 
in the psychological intervention group (five [29%]) and 
no-treatment group (three [60%]). The most com monly 
occurring adverse event in participants receiving 
antipsychotics was medi cation side-effects. One adverse 
event in the psychological intervention group was related 
to trial participation (distress about allocation to 
psychological intervention reported immediately after 
randomisation). Between baseline and 3 months, 
nine of 53 participants with an available PANSS 
assessment had deteriorations of 12·5% or more in 
PANSS total score (five had deteriorations of 25% or 
more): four in the psycho logical intervention group, 
three in the anti psychotics group, one in the combined 
group, and one who did not receive any treatment. At 
6 months, PANSS had deteriorated by at least 25% in 
four patients and by at least 50% in two patients. At 
12 months, one patient had a 25% or more deterioration 
in PANSS (table 6). At 3 months, two partici pants 
receiving antipsychotics were switched to combined 
treatment after 27·5% and 14·3% deteriorations in 
PANSS, and one participant receiving psycho logical 
intervention was switched to combined treatment after a 
24·3% deterioration in PANSS. Adverse effects including 
non-neurological side-effects, metabolic effects, and 
weight gain are summarised in the appendix (pp 21–22). 
Potential unwanted effects of trial participation are also 
included in the appendix (pp 23–24).
Antipsychotics Psychological 
intervention
Antipsychotics plus 
psychological 
intervention
Baseline 22; 74·8 (12·2) 18; 72·9 (9·7) 21; 75·9 (14·8)
3 months 19; 65·6 (15·4) 17; 64·9 (9·9) 17; 64·2 (16·1)
6 months 18; 68·6 (17·3) 16; 59·8 (13·7) 17; 62·0 (15·9)
12 months 9; 55·4 (7·0) 11; 61·3 (12·4) 11; 56·2 (12·3)
Data are n; mean (SD) for patients retained at each follow-up assessment (figure). 
PANSS subscale scores are provided in the appendix (pp 10–11). PANSS=Positive 
and Negative Syndrome Scale.
Table 3: PANSS total scores (intention-to-treat groups)
Antipsychotics Psychological 
intervention
Antipsychotics plus 
psychological 
intervention
≥25%
3 months 8/19 (42%) 7/17 (41%) 8/17 (47%)
6 months 5/18 (28%) 10/16 (63%) 11/17 (65%)
12 months 6/9 (67%) 6/11 (55%) 8/11 (73%)
≥50%
3 months 3/19 (16%) 2/17 (12%) 2/17 (12%)
6 months 4/18 (22%) 5/16 (31%) 5/17 (29%)
12 months 3/9 (33%) 3/11 (27%) 3/11 (27%)
≥75%
3 months 0/19 0/17 1/17 (6%)
6 months 0/18 1/16 (6%) 1/17 (6%)
12 months 0/9 1/11 (9%) 1/11 (9%)
Sample sizes represent number of patients retained at each follow-up assessment 
(figure). ≥25% was conidered minimal improvement and ≥50% was considered a 
good clinical response. Patients are represented more than once if consecutive 
thresholds were met, and for each timepoint.
Table 4: Improvement in Positive and Negative Syndrome Scale total 
score (intention-to-treat groups)
Antipsychotics Psychological 
intervention
Antipsychotics plus 
psychological 
intervention
Baseline 15; 42·1 (10·0) 12; 46·1 (9·3) 18; 42·6 (10·1)
3 months 13; 44·6 (12·3) 11; 47·1 (10·5) 10; 51·8 (8·6)
6 months 15; 49·9 (13·4) 8; 49·4 (7·8) 12; 51·3 (10·7)
12 months 6; 52·7 (12·0) 7; 54·1 (6·9) 9; 59·6 (7·8)
Data are n; mean (SD). Data were missing when participant engagement and 
Positive and Negative Syndrome Scale interviews were prioritised.
Table 5: Questionnaire about Process of Recovery scores (intention-to-
treat groups)
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Discussion
The MAPS trial has shown that a study comparing 
antipsychotics with psychological therapies and a 
combined treatment in adolescents with first-episode 
psychosis is possible, although recruitment challenges at 
some sites indicate that changes might be required. This 
pragmatic pilot and feasibility trial had low attrition 
(<20% up to 6 months), similar attrition across the study 
groups, and a considerable proportion of participants 
adhered to the therapy that they were allocated. However, 
a notable minority of participants did not receive the 
allocated treatment, and recruitment proved challenging, 
particularly at some sites. Therefore, revisions to the 
design and implementation of the trial would be needed 
for a definitive trial. Our recommen dations are given in 
the appendix (pp 25–28).
All three regimens were broadly safe and acceptable, 
with no involuntary hospital admissions and no 
suggestions that psychological interventions in the 
absence of antipsychotic medication were detrimental. 
All three regimens also seemed to provide benefit, with 
mean PANSS scores improving from baseline by 
approximately 6–14 points at 6 months, and 12–20 points 
at 12 months, most of which are within the range 
recognised as clinically important differences; for 
example, the minimal clinically important difference 
thresholds for patient-rated PANSS (11 points)22 and 
clinician-rated PANSS (15 points).16 Participants receiving 
combined treatment had the highest rate of serious 
adverse effects, which is a logical outcome given that 
more treatments being delivered increases the potential 
for unwanted effects. However, combined treatment was 
associated with fewer deteriorations in PANSS total. In 
addition, participants receiving antipsychotics had fewer 
serious adverse events (n=2) than those receiving 
psychological intervention, but more adverse events than 
the psychological intervention and combined groups. No 
serious adverse events were considered related to the 
study treatments. As such, a reasonable conclusion is 
that all treatments confer benefit and each treatment has 
its own adverse effect profile. A definitive test of 
effectiveness is now required.
The delivery of interventions within the trial seemed 
competent. Antipsychotics were administered quickly 
(median of 18 days from randomisation), for a reasonable 
duration (median of 32 weeks), with the majority of 
participants exposed for 6 or more consecutive weeks 
(28 [65%] of 43), and attempts were made to maximise 
benefit for a third of participants allocated to anti-
psychotics by switching to a different antipsychotic. The 
three most commonly prescribed anti psychotics were 
aripiprazole, risperidone, and quetiapine, which reflects 
the clinical practice of UK child and adolescent psychi-
atrists and is consistent with findings of an international 
study of antipsychotic prescribing for children and young 
people with early-onset psychosis.23 Detailed information 
on dosages prescribed in this trial are given in the 
Antipsychotics 
(n=15)†
Psychological 
intervention 
(n=17)†
Antipsychotics 
plus psychological 
intervention 
(n=23)†
No 
treatment 
(n=5)†
Serious adverse events
Participants 2 (13%) 4 (24%) 8 (35%) 4 (80%)
Total events 2 5 11 5
Participants with more than one 
event
0 1 (25%) 2 (25%) 1 (25%)
Type of event
Voluntary psychiatric admission 0 0 3 0
Life threatening (suicide attempt) 0 1 1 1
Serious violent incident 2 2 1 2
Admission to a general medical 
ward for physical condition 
(voluntary)
0 2 1 2
Otherwise considered medically 
significant: overdose of 
medication
0 0 4 0
Otherwise considered medically 
significant: overdose of 
painkillers‡
0 0 1† 0
Adverse events
Participants 13 (87%) 5 (29%) 16 (70%) 3 (60%)
Total events 41 10 35 3
Participants with more than one 
event
9 (69%) 3 (60%) 9 (56%) 0
Type of event
Self-harm 7 6 12 3
Medication side-effect 28 0 17 0
Other adverse event 6 4 5 0
Distress reported regarding 
allocation
0 0 1 0
Deterioration in PANSS total§
3 months
≥12·5% 0/13 3/17 (18%) 6/20 (30%) 0/3
≥25% 0/13 3/17 (18%) 2/20 (10%) 0/3
≥50% 0/13 0/17 0/20 0/3
6 months
≥12·5% 1/13 (8%) 3/16 (19%) 4/19 (21%) 1/3 (33%)
≥25% 1/13 (8%) 2/16 (13%) 2/19 (11%) 1/3 (33%)
≥50% 0/13 1/16 (6%) 1/19 (5%) 0/3
12 months
≥12·5% 1/6 (17%) 2/10 (20%) 2/13 (15%) 0/2
≥25% 0/6 0/10 1/13 (8%) 0/2
≥50% 0/6 0/10 0/13 0/2
Data are n or n (%) for as-treated groups according to treatment received for at least one dose or session. 
PANSS=Positive and Negative Syndrome Scale. *Data could not be retrieved on one participant who withdrew from 
the trial before medical record screening had commenced. †Discrepancies between as-treated (safety) groups here and 
as-treated (treatment received) groups in table 2 result from operationalisation of the criteria. For example, a 
participant taking antipsychotics was classified as receiving antipsychotic monotherapy in table 2 if they received less 
than 6 sessions of psychological intervention, but would be antipsychotics plus psychological intervention in the 
safety assessment if they had received at least one session but less than six. ‡Ingested five painkillers. §In those 
patients who had a PANSS assessment at each timepoint; patients are represented more than once if consecutive 
thresholds were met, and for each assessment time.
Table 6: Adverse events and deterioration in PANSS total score (as-treated groups)*
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appendix (p 8). Psychiatrists prescribed the antipsychotics, 
as per normal practice, to achieve control of psychotic 
symptoms within the British National Formulary 
recommended dosages. The NICE guidance for 
management of psychosis and schizo phrenia in 
adolescents (CG155)10 recommends starting with a low 
dose of an antipsychotic and gradually increasing. The 
doses in this trial were generally low, except for the 
highest mean dose of risperidone, which was greater than 
the 2 mg normally recommended for first-episode 
psychosis. Olanzapine was an unusual choice for first-
episode psychosis, as it is no longer recommended as a 
first-line treatment due to concerns about its effects on 
metabolism and weight gain.10 The provision of 
psychological therapies was also consistent with good 
practice, with first appointments being offered quickly 
(median time from randomisation of approxi mately 
2 weeks), and most participants receiving 6 or more 
sessions (32 [82%] of 39 participants in the mono therapy 
and combined groups). With regard to those allocated 
to receive an offer of family intervention, 21 (54%) of 
39 received at least one session, with the mean number 
being 3–4 sessions. These findings are reflective of family 
intervention being offered to all of our participants, but 
the choice regarding uptake residing with the young 
person themselves, as some adolescents will not consent 
to family involvement, and again is a pragmatic reflection 
of real-world com plexities in evaluating multiple psycho-
social interventions; however, our findings do suggest 
that family intervention might be less acceptable than 
CBT to adolescents with first-episode psychosis.
Our trial had several limitations. The feasibility trial 
design and small sample size means that caution must be 
taken in interpreting any statistical tests and significance 
values. With regard to the integrity of treatment allocation, 
the proportions of patients receiving interventions as 
allocated ranged between 52% and 64%, although the 
proportion receiving an additional, unallocated interven-
tion was only 13%. These proportions reflect real-world 
behaviours, in that many people frequently do not adhere 
with treatment regimens exactly as prescribed; similar 
rates of non-adherence are commonly observed in trials 
of antipsychotic medication, and psychological therapy 
trials are often confounded by participants receiving 
additional medications and other psychosocial inter-
ventions. In this trial, we were unable to mask participants 
to allocation, which might represent a source of bias. All 
participants met the entry criteria, including presentation 
to services with psychosis symp toms, being under the 
care of a psychiatrist within an EIP service or CAMHS, 
and scoring 4 or higher on the PANSS delusions and 
hallucinations subscales for at least 7 days. However, 
hallucinations can be prevalent in the general population 
of adolescents, with a median of 7·5% of adolescents 
(aged 13–18 years) reporting such experiences in a meta-
analysis of 19 population-based studies.24 Although our 
sample was fairly homogeneous in terms of age and 
experience of early-onset psychosis and need for 
psychiatric care, only 67% had a diagnosis of a psychotic 
disorder recorded in their notes at baseline, with the most 
common entry being first-episode psychosis and the most 
common formal ICD-10 diagnosis being unspecified non-
organic psychosis (code F29). Comorbidities were also 
frequent in our sample, including high rates of caseness 
for anxiety, depression, and autistic spectrum disorders, 
and high levels of drug and alcohol use. The heterogeneity 
of our population reflects the reality of both early 
intervention services that embrace diagnostic uncertainty, 
and the complexity of an emerging clinical picture in 
adolescents presenting with distressing psychotic 
experiences, often with clinically significant complexities. 
However, this diagnostic heterogeneity might result in 
heterogeneity in patient responses to both psychological 
interventions and antipsychotics, which might affect the 
appropriateness and cost to benefit ratio of each treatment 
relative to adverse effects. For example, people with 
psychotic symptoms in the context of depression or post-
traumatic stress disorder might be more likely to benefit 
from psychological intervention, and those with psychotic 
symptoms in the context of autism spectrum disorder 
might be more likely to show treatment resistance to 
antipsychotics.25
The clinical heterogeneity of a help-seeking adolescent 
population might require a tailored and personalised 
treatment approach delivered via an adaptive trial design. 
In a future definitive trial, a baseline adolescent diagnostic 
assessment with a validated structured tool such as the 
Development and Wellbeing Assessment26 might provide 
a detailed picture of the range of adolescent psycho-
pathology and predictors of treatment response.
Our trial also had limitations with regard to the 
initiation and delivery of medication. Although we 
recommended that prescribing psychiatrists followed 
NICE guidelines, we did not systematically monitor 
fidelity to NICE prescribing guidance, and we did not 
assess drug plasma concentrations, which might be 
required to identify a potential cause of non-response;27 
a definitive trial should consider these options. Our 
more rigorous monitoring of fidelity to the delivery of 
psychological interventions compared with antipsychotics 
might have resulted in a bias that favoured psychological 
intervention; the proportion of patients showing a good 
response to antipsychotics (≥50% improvement in 
PANSS; 4 [22%] of 18 participants at 6 months) was low 
compared with a 2018 trial showing remission in 
287 (64%) of 446 adult patient receiving antipsychotics 
for first-episode psychosis.28 Low response in our trial 
could be the result of non-adherence, or could be 
specifically related to specific characteristics of an 
adolescent population, including common comorbidities, 
or the long duration of untreated psychosis that was 
observed in our sample. A placebo condition would have 
been helpful in interpreting treatment efficacy (and was 
used in a 2020 study of CBT with and without 
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antipsychotics29), particularly in relation to the effects of 
antipsychotics; however, a placebo condition might not 
be needed to investigate the pragmatic effectiveness of 
interventions in NHS settings, and was unnecessary for 
a feasibility study that was not designed to investigate 
efficacy. Because all participants were receiving care 
from an EIP service or CAMHS, we cannot exclude the 
possibility that any benefits observed are attributable to 
factors such as effective care coordination, engagement, 
and crisis management, rather than the specific active 
treatments provided by the trial. The diagnostic 
heterogeneity of our sample, although reflecting clinical 
realities of early interven tion provision, also represents a 
limitation, given that different diagnostic groups might 
exhibit differential treatment responses. The omission of 
a diagnostic interview at the point of entry to the study is 
also a limitation. Some of the less prioritised secondary 
outcome measures (ie, self-report scales) had large 
amounts of missing data (as a result of minimising the 
effect of participant burden on attrition) and a high 
number of blood test results were missing because many 
young people were reluctant to consent to these. As such, 
a future trial should reduce the number of secondary 
assessments. The duration of follow-up should be at least 
12 months to allow for evaluation of the longevity of 
treatment effects. Our trial had several challenges in 
recruitment, including lower incidence in rural areas, 
polarised opinions regarding treatment options in 
potential referrers and prescribers (as addressed in our 
related MAPS trial paper30), and integration between 
the research and clinical teams; therefore, site selection 
for a definitive trial should be based on prevalence of 
adolescent first-episode psychosis, and willing ness of 
clinicians to recognise clinical equipoise and the need for 
a trial, and, thus, to randomly allocate treatments. In 
addition, the upper age limit could be increased from 
18 to 25 years, as definitions of adoles cence often extend 
to 25 years of age (eg, the WHO definition of youth), 
which would widen the potential pool of participants. 
More extensive recommendations for a clinical trial are 
considered in the appendix (pp 25–28).
The main implication of this trial is that an adequately 
powered effectiveness trial is now required to provide 
evidence regarding the relative effectiveness of anti-
psychotic medication and psychological therapies (CBT 
and family intervention) in adolescents with early-onset 
psychosis. On the basis of our trial, it seems reasonable 
to support young people with early-onset psychosis and 
their families (in the absence of immediate risk to 
themselves or others) to make informed treatment 
choices as outlined in the NICE guidelines.
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